Informatie:
Fout:
ID
15301
Beschrijving
Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses; ODM derived from: https://clinicaltrials.gov/show/NCT01487096
Link
https://clinicaltrials.gov/show/NCT01487096
Trefwoorden
Versies (1)
- 25-05-16 25-05-16 -
Geüploaded op
25 mei 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Multiple Sclerosis NCT01487096
Eligibility Multiple Sclerosis NCT01487096
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Sclerosis NCT01487096
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
MS
Item
clinically confirmed multiple sclerosis [ms];
boolean
C0026769 (UMLS CUI [1])
edss
Item
expanded disability status scale [edss] score less or equal to 6;
boolean
C0451246 (UMLS CUI [1])
two documented relapses
Item
two documented relapses in the previous 3 years, and one clinical relapse during the preceding year;
boolean
C0277556 (UMLS CUI [1])
MRI
Item
screening magnetic resonance imaging [mri] scan fulfilling the criteria for a diagnosis of ms.
boolean
C0024485 (UMLS CUI [1])
comorbidity
Item
clinically relevant cardiovascular, hepatic, hematologic, neurological, endocrine or other major systemic disease;
boolean
C0009488 (UMLS CUI [1])
pregnant or nursing woman
Item
pregnant or nursing woman;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
contraceptive use
Item
wish to parent children during the trial or following the trial (men and women were required to practice effective contraception during the trial and for 24 months after drug discontinuation);
boolean
C1999124 (UMLS CUI [1])
pharmaceutical preparations
Item
prior treatment with interferon [ifn], gamma-globulin, glatiramer acetate, or other noncorticosteroid immunomodulatory therapies in the 4 months prior to the trial;
boolean
C0279030 (UMLS CUI [1])
C0860681 (UMLS CUI [2])
C0289884 (UMLS CUI [3])
C1963758 (UMLS CUI [4])
C0860681 (UMLS CUI [2])
C0289884 (UMLS CUI [3])
C1963758 (UMLS CUI [4])
immunosuppressant agents
Item
use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;
boolean
C0021081 (UMLS CUI [1])
comorbidity limiting compliance behavior
Item
any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.
boolean
C0009488 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,3])
not intended to contain all considerations
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean